KR102269861B1 - 광감제 및 키토산의 컨쥬게이트, 및 이의 용도 - Google Patents

광감제 및 키토산의 컨쥬게이트, 및 이의 용도 Download PDF

Info

Publication number
KR102269861B1
KR102269861B1 KR1020207019532A KR20207019532A KR102269861B1 KR 102269861 B1 KR102269861 B1 KR 102269861B1 KR 1020207019532 A KR1020207019532 A KR 1020207019532A KR 20207019532 A KR20207019532 A KR 20207019532A KR 102269861 B1 KR102269861 B1 KR 102269861B1
Authority
KR
South Korea
Prior art keywords
compound
cell
group
molecule
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020207019532A
Other languages
English (en)
Korean (ko)
Other versions
KR20200085380A (ko
Inventor
크리스티안 버그
앤덜스 하그세트
마르 마손
비베크 에스. 가와레
Original Assignee
피씨아이 바이오테크 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피씨아이 바이오테크 에이에스 filed Critical 피씨아이 바이오테크 에이에스
Publication of KR20200085380A publication Critical patent/KR20200085380A/ko
Application granted granted Critical
Publication of KR102269861B1 publication Critical patent/KR102269861B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207019532A 2012-05-15 2013-05-14 광감제 및 키토산의 컨쥬게이트, 및 이의 용도 Expired - Fee Related KR102269861B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1208548.6A GB201208548D0 (en) 2012-05-15 2012-05-15 Compound and method
GB1208548.6 2012-05-15
PCT/EP2013/059968 WO2013189663A1 (en) 2012-05-15 2013-05-14 Conjugate of a photosensitiser and chitosan and uses thereof
KR1020147035218A KR20150013803A (ko) 2012-05-15 2013-05-14 광감제 및 키토산의 컨쥬게이트, 및 이의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035218A Division KR20150013803A (ko) 2012-05-15 2013-05-14 광감제 및 키토산의 컨쥬게이트, 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20200085380A KR20200085380A (ko) 2020-07-14
KR102269861B1 true KR102269861B1 (ko) 2021-06-28

Family

ID=46458880

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207019532A Expired - Fee Related KR102269861B1 (ko) 2012-05-15 2013-05-14 광감제 및 키토산의 컨쥬게이트, 및 이의 용도
KR1020147035218A Ceased KR20150013803A (ko) 2012-05-15 2013-05-14 광감제 및 키토산의 컨쥬게이트, 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147035218A Ceased KR20150013803A (ko) 2012-05-15 2013-05-14 광감제 및 키토산의 컨쥬게이트, 및 이의 용도

Country Status (23)

Country Link
US (1) US9901636B2 (https=)
EP (1) EP2849791B1 (https=)
JP (1) JP6456284B2 (https=)
KR (2) KR102269861B1 (https=)
CN (1) CN104780941B (https=)
AU (1) AU2013279748B2 (https=)
BR (1) BR112014028315B1 (https=)
CA (1) CA2873259C (https=)
DK (1) DK2849791T3 (https=)
ES (1) ES2682762T3 (https=)
GB (1) GB201208548D0 (https=)
HR (1) HRP20181276T1 (https=)
HU (1) HUE039725T2 (https=)
IN (1) IN2014DN09418A (https=)
MX (1) MX362237B (https=)
NZ (1) NZ630582A (https=)
PL (1) PL2849791T3 (https=)
PT (1) PT2849791T (https=)
RU (1) RU2675830C2 (https=)
SG (1) SG11201407603YA (https=)
SI (1) SI2849791T1 (https=)
WO (1) WO2013189663A1 (https=)
ZA (1) ZA201408406B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
AU2014390262B2 (en) 2014-04-11 2020-11-26 Pci Biotech As Method of treating melanoma
EP3185901B1 (en) 2014-08-28 2023-10-04 PCI Biotech AS Compound and method
CN104650259A (zh) * 2015-01-23 2015-05-27 广西大学 一种纳米孔壳聚糖四(4-磺酸基苯基)金属卟啉微球及其制备方法和使用方法
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
GB201511159D0 (en) 2015-06-24 2015-08-05 Univ Nottingham Controlled cell delivery vehicle and treatment of tumours
WO2017162918A1 (en) 2016-03-22 2017-09-28 Åbo Akademi University Polysaccharide derivatives as optical brightening agents
KR20190013289A (ko) * 2017-08-01 2019-02-11 순천대학교 산학협력단 수용성 키토산을 포함하는 나노광증감제
GB201801169D0 (en) 2018-01-24 2018-03-07 Pci Biotech As Method
CN108892743A (zh) * 2018-05-28 2018-11-27 南京工业大学 用于光动力抗菌的纳米光敏剂，其制备方法及应用
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
CN115399328B (zh) * 2021-05-27 2024-03-22 中国科学院化学研究所 一种多糖基杀菌材料及其制备方法和应用
GB202115451D0 (en) 2021-10-27 2021-12-08 Pci Biotech As Method
CN117285662A (zh) * 2022-06-15 2023-12-26 南京仁为医药科技有限公司 一种壳聚糖双吡啶季铵盐及其制备方法
GB202301312D0 (en) 2023-01-30 2023-03-15 Pci Biotech As Method and product

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101024087A (zh) * 2007-03-28 2007-08-29 长沙理工大学 壳聚糖－多肽－卟啉纳米药物载体及其制备和应用
US20100222538A1 (en) * 2007-04-23 2010-09-02 Ick-Chan Kwon Novel photosensitizer based on polymer derivatives-photosensitizer conjugates for photodynamic therapy
WO2010143942A1 (en) * 2009-06-12 2010-12-16 Erasmus University Medical Center Rotterdam Targeted nano-photomedicines for photodynamic therapy of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
JP2002241307A (ja) * 2001-02-19 2002-08-28 Yasuhiko Tabata 光増感剤を含有する超音波治療用活性酸素発生剤
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
GB0415663D0 (en) 2004-07-13 2004-08-18 Psimei Pharmaceuticals Plc Compound
WO2007023398A2 (en) 2005-05-16 2007-03-01 Universite De Geneve Compounds for photochemotherapy
JP4287411B2 (ja) * 2005-07-01 2009-07-01 株式会社東芝 仮想メモリシステムおよび仮想記憶方法
KR20090047872A (ko) 2007-11-08 2009-05-13 인제대학교 산학협력단 신규 카보하이드레이트 복합 클로린 화합물 및 이의제조방법
WO2009077908A1 (en) 2007-12-14 2009-06-25 University Of Lausanne Colloidal particle comprising multivalent cyclic anions
KR101076717B1 (ko) 2008-11-07 2011-10-26 재단법인대구경북과학기술원 광역학 치료용 나노구조체 및 그 제조방법
US20100129432A1 (en) 2008-11-25 2010-05-27 Taipei Medical University Microorganism-killing combination
WO2010126179A1 (ko) 2009-04-29 2010-11-04 다이아텍코리아 주식회사 클로린 e6-엽산 결합 화합물 및 키토산을 함유하는 암 치료용 약학적 조성물
KR100918811B1 (ko) 2009-04-29 2009-09-25 다이아텍코리아 주식회사 클로린 ｅ６-엽산 결합 화합물 및 키토산을 함유하는 암 치료용 약학적 조성물
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
KR101228106B1 (ko) 2010-01-21 2013-02-01 광주과학기술원 피부투과도, 세포유입 및 종양전달성이 증가된 나노운반체
KR101250150B1 (ko) * 2010-10-29 2013-04-04 가톨릭대학교 산학협력단 광역학치료를 위한 고분자-광응답제 접합체 및 이의 제조방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101024087A (zh) * 2007-03-28 2007-08-29 长沙理工大学 壳聚糖－多肽－卟啉纳米药物载体及其制备和应用
US20100222538A1 (en) * 2007-04-23 2010-09-02 Ick-Chan Kwon Novel photosensitizer based on polymer derivatives-photosensitizer conjugates for photodynamic therapy
WO2010143942A1 (en) * 2009-06-12 2010-12-16 Erasmus University Medical Center Rotterdam Targeted nano-photomedicines for photodynamic therapy of cancer

Also Published As

Publication number Publication date
ZA201408406B (en) 2016-02-24
NZ630582A (en) 2017-02-24
MX2014013516A (es) 2015-11-13
JP2015516496A (ja) 2015-06-11
KR20200085380A (ko) 2020-07-14
CN104780941A (zh) 2015-07-15
WO2013189663A1 (en) 2013-12-27
KR20150013803A (ko) 2015-02-05
BR112014028315A2 (pt) 2017-10-24
PT2849791T (pt) 2018-10-04
CN104780941B (zh) 2019-01-15
HK1203850A1 (en) 2015-11-06
RU2014150569A (ru) 2016-07-10
EP2849791B1 (en) 2018-07-04
US20150202293A1 (en) 2015-07-23
GB201208548D0 (en) 2012-06-27
HUE039725T2 (hu) 2019-01-28
HRP20181276T1 (hr) 2018-11-16
RU2675830C2 (ru) 2018-12-25
SI2849791T1 (sl) 2018-10-30
AU2013279748B2 (en) 2018-08-02
PL2849791T3 (pl) 2019-03-29
AU2013279748A1 (en) 2014-11-20
ES2682762T3 (es) 2018-09-21
EP2849791A1 (en) 2015-03-25
JP6456284B2 (ja) 2019-01-23
MX362237B (es) 2019-01-09
CA2873259C (en) 2021-08-03
US9901636B2 (en) 2018-02-27
IN2014DN09418A (https=) 2015-07-17
SG11201407603YA (en) 2014-12-30
DK2849791T3 (en) 2018-08-13
CA2873259A1 (en) 2013-12-27
BR112014028315B1 (pt) 2022-02-22

Similar Documents

Publication Publication Date Title
KR102269861B1 (ko) 광감제 및 키토산의 컨쥬게이트, 및 이의 용도
Wei et al. NIR-light triggered dual-cascade targeting core-shell nanoparticles enhanced photodynamic therapy and immunotherapy
KR102052225B1 (ko) 관능성 pla-peg 공중합체, 그의 나노입자, 그의 제조법, 및 표적화 약물 전달 및 영상화를 위한 용도
Khandare et al. Novel polymeric prodrug with multivalent components for cancer therapy
Chen et al. Theranostic prodrug vesicles for imaging guided codelivery of camptothecin and siRNA in synergetic cancer therapy
JP2020526519A (ja) 分枝多官能性マクロモノマーおよび関連ポリマーならびにそれらの使用
Zhang et al. Sulfonium-driven neoantigen-released DNA nanodevice as a precise vaccine for tumor immunotherapy and prevention
JPWO2005095494A1 (ja) 新規水溶性フラーレン、その製造方法およびそれを含む活性酸素発生剤
JP2015155442A (ja) 化合物及び生物学的材料並びにそれらの使用
Glass et al. Optimizing mannose “click” conjugation to polymeric nanoparticles for targeted siRNA delivery to human and murine macrophages
Pan et al. A tumor-targeting porphyrin-micelle with enhanced STING agonist delivery and synergistic photo-/immuno-therapy for cancer treatment
Gaware et al. Endosome targeting meso-tetraphenylchlorin–chitosan nanoconjugates for photochemical internalization
Yin et al. Formulation and evaluation of lipidized imiquimod as an effective adjuvant
CN119504769B (zh) 一种靶向her2的抗体偶联金（ⅲ）卟啉药物及其合成与肿瘤治疗应用
US10561730B2 (en) Plant virus particles for delivery of photosensitive agents
KR101138438B1 (ko) 스피루리나로부터 클로로필 ａ 및 광민감제 제조방법
CN104208709A (zh) 一种脑靶向水溶性药物负载及其制备方法与应用
US20250304545A1 (en) Water-soluble heterocyclyl polymethine chromophores
HK1203850B (en) Conjugate of a photosensitiser and chitosan and uses thereof
KR101106756B1 (ko) 스피루리나로부터 클로로필 ａ 및 광민감제 제조방법
KR101138437B1 (ko) 스피루리나로부터 클로로필 ａ 및 광민감제 제조방법
Fernandez-Megia Synthesis of multi-functional dendrimers for targeted delivery of nucleic acids
KR20120016573A (ko) 스피루리나로부터 클로로필 ａ 및 광민감제 제조방법
Wu Genome-Free Viral Capsids for Targeted Drug Delivery to Breast Cancer

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250623

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250623

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250623